Live microbials to boost Anti-SARS-CoV-2 immunity clinical trial (Live BASIC trial): a triple-blind randomized controlled trial

20250 citationsJournal Articlehybrid Open Access

Authors

Daniel B. Horton · Rutgers, The State University of New Jersey

Rahul Ukey · Rutgers, The State University of New Jersey

Abhilasha Madhvi · Rutgers, The State University of New Jersey

Tracy Andrews · Rutgers, The State University of New Jersey

Veenat Parmar · Rutgers, The State University of New Jersey

Nancy Reilly · Rutgers, The State University of New Jersey

Sanna M. Mäkelä

Abstract

The live microbial consortium OL-1 was well-tolerated and associated with slightly increased anti-SARS-CoV-2 IgG levels in previously infected, unvaccinated adults at standard, but not high, dosage. Further research should confirm these findings and their clinical implications in larger populations. This study was registered on ClinicalTrials.gov (NCT04847349) on April 14, 2021.

Topics & Keywords

SARS-CoV-2 and COVID-19 Research Antibiotic Use and Resistance Immune responses and vaccinations

Publication Details

Published in: Infection

Volume 54, Issue 1, pp. 473-485

DOI: 10.1007/s15010-025-02697-4

Field-Weighted Citation Impact: 0.00

Command Palette

Live microbials to boost Anti-SARS-CoV-2 immunity clinical trial (Live BASIC trial): a triple-blind randomized controlled trial

Authors

Abstract

Topics & Keywords

Publication Details